US Tuberculosis Treatment Market Statistics:

Market Size in 2025: USD 2.32 Billion

Market Size in 2032:  USD 2.87 Billion

Market Growth Rate 2026-2032: CAGR 3.61%
According to The Report Cube’s latest research study US Tuberculosis Treatment Market reached a value of nearly USD 2.32 Billion in 2025. The market is assessed to grow at a CAGR of around 3.61%, during the forecast period of 2026-2032 to attain a value of around USD 2.87 Billion in 2032.

Download Free Sample Copy of The US Tuberculosis Treatment Market report @ https://www.thereportcubes.com/request-sample/us-tuberculosis-treatment-market

US Tuberculosis Treatment Market Drivers:

·       Driver: Increasing Prevalence of Tuberculosis to Elevate the Market Demand

The US, a developed nation, is still witnessing a steady surge in TB incidence, specifically among immunocompromised & foreign-born individuals.  Also, TB treatment programs & related medications are increasing as a result of the growing incidence of TB.

According to the report, prominent players operating in the market include:

·       Sanofi

·       Pfizer Inc.

·       Novartis AG

·       Merck & Co., Inc.

·       Cipla Ltd.

·       Macleods Pharmaceuticals Ltd.

·       Others

Get Detailed Insights from the Complete Report@

https://www.thereportcubes.com/report-store/us-tuberculosis-treatment-market

Key Market Segmentation

o   Market Share, By Disease Type

o   Active TB

o   Latent TB

o   Market Share, By End User

o   Hospital Pharmacies

o   Retail Pharmacies

o   Online Pharmacies

o   Others

o   Market Share, By Route of Administration

o   Oral

o   Parenteral

o   Others

o   Market Share, By Dosage Form

o   Tablets

o   Capsules

o   Injections

o   Others

o   Market Share, By Therapy

o   First-Line Therapy

o   Second-Line Therapy

Recent News and Developments in US Tuberculosis Treatment Market

• Sanofi introduced a joint program with the CDC to support treatment adherence for drug-resistant TB utilizing digital pill-tracking solutions.
• Pfizer Inc. commenced a Phase II clinical trial assessing a novel anti-mycobacterial agent effective against multidrug-resistant TB, targeting to expand its infectious disease portfolio.

About The Report Cube

The Report Cube is the largest marketplace in UAE for research reports, delivering insightful data to empower more informed decisions. As a trusted market research and consulting firm, we provide syndicated reports, customized research solutions, and global market intelligence across 800+ industries.

With 1,700+ research experts and a client base that includes Fortune 500 companies, we are dedicated to empowering the future with AI, transforming industries, and igniting unprecedented business growth

Contact Us:

The Report Cube,

Burjuman Business Tower, Burjuman, Dubai

Enquiry for any support - https://www.thereportcubes.com/contact-us

Our Blogs - https://www.thereportcubes.com/blogs